≥95% by HPLC
Filippakopoulos, P., et al., Nature. 468(7327):1067-73 (2011).
Application Reference(s): 1. The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains (2017)2. Analysis of Chromatin Opening in Heterochromatic Non-Small cell Lung Cancer Tumor-Initiating Cells in Relation to DNA-Damaging Antitumor Treatment (2017)3. Notch Inhibition Enhances Cardiac Reprogramming by Increasing MEF2C Transcriptional Activity (2017)4. Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations (2017)5. Erratum: BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin (2017)6. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia (2017)7. Uncovering BRD4 hyperphosphorylation associated with cellular transformation in NUT midline carcinoma (2017)8. Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function (2015) 9. GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1 (2015) 10. BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen (2014) 11. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology (2014) 12. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma (2013)
